Encellin, a biotechnology company pioneering Encapsulated Cell Replacement Therapy (ENCRT), today announced interim clinical ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Encelto is the first FDA-approved treatment for macular ...

ELK GROVE VILLAGE, Ill., April 1, 2025 /PRNewswire/ — Orsini, a leader in rare disease pharmacy solutions, has been selected by Neurotech Pharmaceuticals, Inc., as the exclusive specialty pharmacy ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

The first treatment for macular telangiectasia type 2 is set to enter the market following U.S. FDA approval of NT-501 (revakinagene taroretcel) from Neurotech Pharmaceuticals Inc., a privately held ...

LAS VEGAS, Dec. 9, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and ...

Please provide your email address to receive an email when new articles are posted on . The development of drug delivery platforms that offer sustained release of therapeutic agents in the retina ...

Revakinagene taroretcel-lwey is the first FDA-approved treatment for macular telangiectasia type 2, a progressive neurodegenerative retinal disease. The therapy uses an encapsulated cell-based gene ...